Connect with us


Green Thumb Industries Inc (OTCMKTS:GTBIF) Inaugurates First Store – Rise Paterson In New Jersey



Green Thumb Industries Inc (OTCMKTS:GTBIF) has inaugurated its first store – Rise Paterson in New Jersey on December 21, 2019. It is the 37th store in the US. Ben Kovler, Chief Executive Officer and founder of Green Thumb, said the company is grateful to Phil Murphy, the governor of New Jersey, and Andre Sayegh, Mayor, for their vision, commitment and leadership extended to the medical community. It allows the company to serve the community in New Jersey and Paterson with new jobs.

63,000 registered patients

The medical marijuana program in New Jersey has registered a patient base of 63,000. Around one thousand physicians are serving the community in the state to treat post-traumatic disorder, anxiety, opioid use disorder, and chronic pain.

Inaugurates a retail location in Pennsylvania

Green Thumb is pleased to inaugurate its 9th retail location – Rise New Castle in Pennsylvania. The company targets to offer high-quality cannabis products to the patients in this state. Other locations of Rise include the King of Prussia, Hermitage, Erie, Steelton, Carlisle, York, and Mechanicsburg.

Erin Orrico, investor relations coordinator of Lawrence County Regional Chamber of Commerce, commenting on the development said he welcomes the project. The medical program will surely benefit the patients in Pennsylvania.

The medical marijuana program in the state has a registered patient base of 180,000. Medical cannabis sales in the state have exceeded $500 million after opening the dispensaries two years ago.

Better than expected revenues

Green Thumb has posted robust revenues of $68 million in Q3 2019, an increase of 295.34% from the same period last year. It has reduced the net loss to $17.1 million in Q3 from $9.4 million in Q2. Ben said the company is pleased with another strong quarter. The company has improved its profitability and expects to scale up the retail business and consumer products. Going forward, financial flexibility and ample liquidity will support its growth plans. Green Thumb expects to post total sales of $200 million in 2019, ending on a strong note.

Green Thumb has finalized the sale and leaseback accord with Innovative Industrial Properties for its Pennsylvania facility after Q3. The company will use the proceeds of $39.6 million from this deal for strategic expansion.


The Growing Case for Cannabis Global Inc (OTCMKTS:MCTC)



MCTC Holdings Inc (OTCMKTS:MCTC), now doing business now as Cannabis Global, Inc. (MCTC), is starting to look like an increasingly interesting stock in the small-cap cannabis space for a number of reasons, prompting our analysis here as part of our mission to provide insights into under-the-radar speculative opportunities in the cannabis, CBD, and hemp sector.

From a macro perspective, one can easily make a case that the overall sector has transitioned from persistent, glut-induced headwinds to post-purge structural tailwinds. In a robust long-term growth thesis, that’s the crucial moment of opportunity. It is imperative for aggressive investors to find new ways to position at this stage given this transition.


The Big Point

MCTC Holdings Inc (OTCMKTS:MCTC) demands special attention for two key reasons. First, the company is right now making the jump from development-stage operations to full commercialization of its base of proprietary IP. Second, this is one of the very few IP-heavy plays in the cannabis space, with robust R&D and a strong portfolio of patents now in process with the USPTO.

That latter point is especially important because the company’s IP continues to expand as a market-leading foundation, with a growing list of partners pining for access to infusion methods in the edibles space, and because the edibles niche is increasingly looking like the big opportunity as cannabis edges toward universal mainstream popularity.


Laying a Foundation

For example, the company just announced the signing of a definitive, five-year agreement for the production of cannabis edibles and beverages in conjunction with licensed California cannabis operator, Magnolia Extracts, LLC. Under the terms of the agreement, Cannabis Global will provide access to its trade secrets and patent pending technologies for chemical-free cannabis and hemp infusions in the production of tetrahydrocannabinol (THC) containing edibles and beverages.

“This deal represents an enormous escalation in terms of our positioning in the California cannabis edibles and beverages marketplace,” stated Arman Tabatabaei, CEO of Cannabis Global. “We will be working closely with Magnolia and look forward to a rapid path to market for these innovative products. We have strong reason to believe we will see a relatively quick expansion in distribution footprint given the prepotency of demand we are seeing among potential distribution partners already. The Magnolia site has recently been modified to our specifications and is now complete. We are looking forward to moving out of our initial stage of development and into full-scale production. This Agreement is a game-changing development with strong tangible implications for our performance this year.”


The Crux of the Matter

Remember: the big driver of this whole theme is the inexorable trend toward universal legalization of cannabis-based products. If you have any doubts, it’s time to do a personal reality check. The art of successful speculative investing is driven by forming derivative conclusions around a core idea that commands conviction. In this case, the inevitability of the long-term trend toward increasing mainstream integration of cannabis products as legal doors open step by step is that core idea.

From there, the most interesting opportunities are unappreciated and underpriced companies that have built a foundation of valuable proprietary assets that have the potential to increase in applied market value by huge leaps as they become essential in the ecosystem of the market phenomenon in question.

We see Cannabis Global, Inc. (MCTC) as precisely that kind of opportunity right now. The stock has yet to garner attention from the crowd. But it has a rapidly growing role as a core technology provider for many other companies building strong market positions in the industry.


The Only “Varin”

Aside from its formidable edibles infusion IP, the company has also recently made big strides toward establishing a new cannabinoid market with its “Project Varin”. This is potentially a huge future driver of growth for the company because it represents a segment with enormous demand possibilities and virtually no competition. That’s precisely where an IP-driven model has the most potent impact.

Project Varin refers to the company’s initiative to develop new delivery systems for varin cannabinoids. THC-V, which is one of the best known Varins, is becoming known within the cannabinoid sciences arena as the ‘Skinny Cannabinoid’ due to its purported appetite suppression qualities, and its possible use as a treatment against obesity-associated glucose intolerance

The project has already yielded strong results, including a research breakthrough in the form of a new tetrahydrocannabivarin (THC-V) delivery system providing for sustained release of the cannabinoid over a predetermined period of time and two other delivery systems for immediate release.

“While these developments add to our growing list of intellectual property, these are much more than technologies that will sit on a shelf,” commented Arman Tabatabaei, CEO of Cannabis Global. “We have already integrated both the sustained and immediate release versions into beverage products that we expect to be available to consumers next month. We believe the field of minor and exotic cannabinoids will grow substantially this year with several product introductions. We are extremely excited at the prospect of being a first mover in this emerging market segment.”


This article is part of Networks. Read the Networks Disclaimer.

Continue Reading


CBD has Bottomed… What to Do Now (CVSI, GCGX, CWBHF, TRTC, MJNA)



The CBD industry has been one of the hardest hit market segments over the past 18 months. But the long-term structural growth trend continues to look robust. The disconnect is about supply. There was a glut as tons of pretenders and frauds purported to have a viable model. The bear has done its job and shut most of them down.

Now, in the aftermath, with the undergrowth burnt up in the fire, the survivors could be set to run with the structural theme still intact. That provides investors with an impetus to being to pick up the pieces off the floor and possible score big wins with a speculative mindset.

With that in mind, we take a look at some of the most promising names still standing, and expanding, as the new dawn pushes back above the horizon for CBD stocks.


CV Sciences Inc (OTCMKTS:CVSI)

CV Sciences Inc bills itself as a company that operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and, a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors.

At one point, this was the poster child for the space, ramping to over $7/share before being toppled by a Citron bear research piece related to intellectual property. It remains an interesting opportunity, but demands some extra due diligence.

The stock has suffered a bit of late, with shares of CVSI taking a hit in recent action, down about -5% over the past week. But action around the $0.45/share zone will be telling. Thus far, the stock appears to be signaling potential for a “higher low”, which suggests a longer-term bottom was put in place in March and a new upside phase is being cemented into place as fresh capital flows crowd onto the bid.

A break about the 50-day MA (around $0.54) would be a major signal.


Global Consortium Inc. (OTCMKTS:GCGX)

Global Consortium Inc. (OTCMKTS:GCGX) owns Indulge Oils (, a cannabis distillate which is currently being manufactured and marketed in California.

The company is also building America’s First Cannabis Mall in Sacramento, CA which when completed will house Manufacturing, Distribution, Delivery, Retail, Testing, and Cultivation all under one 64,000 square foot building. The Mall will house the largest Manufacturing facility of THC and CBD Distillate and Edibles believed to be operational in the United States. Global Consortium has leased 25,000 Square feet of the building with a purchase option, the Company is working to secure a first right of refusal for the remaining 39,000 square feet.

Indulge Oils is a premium “pesticide free” product sought after brand as it is known for its purity and high quality. Indulge Oils produces clean and pure oils that do not contain any residual particles, are non-toxic and non-carcinogenic. This is why Indulge Oils commands a premium for its oils and cartridges. Global Consortium, Inc. executed a 5-year lease with an option to purchase 25,000 square feet in Sacramento, CA.

Global Consortium Inc. (OTCMKTS:GCGX) is currently also expanding into the state of Florida.

There has been substantial progress in California with licensing and permitting. They are now ready to do full manufacturing for the Indulge Oils line. Dwyer also announced that GCGX will begin working Florida on a new CBD line, the upcoming elimination off all remaining convertible debt, and what is next for GCGX in 2020.


Charlotte’s Web Holdings Inc (OTCMKTS:CWBHF)

Charlotte’s Web is perhaps the most established leader in the space in terms of the North American CBD market. The company makes 100% hemp-based cannabidiol wellness products, including CBD hemp oils, capsules, topicals, and pet products that feature CBD hemp oil extracts.

CWBHF hasn’t really done much of anything over the past week, with shares logging no net movement over that period. Shares of the stock have powered higher over the past month, rallying roughly 27% in that time on strong overall action.

Charlotte’s Web Holdings Inc (OTCMKTS:CWBHF) managed to rope in revenues totaling $30.1M in overall sales during the company’s most recently reported quarterly financial data — a figure that represents a rate of top line growth of 6.4%, as compared to year-ago data in comparable terms. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($88.9M against $38.2M).


Terra Tech Corp (OTCMKTS:TRTC)

Terra Tech trumpets itself as a vertically integrated cannabis-focused agriculture company. The company operates in two segments, Herbs and Produce Products; and Cannabis Dispensary, Cultivation and Production.

TRTC has had a rough past week of trading action, with shares sinking something like -5% in that time. That said, chart support is nearby and we may be in the process of constructing a nice setup for some movement back the other way. Over the past month, shares of the stock have suffered from clear selling pressure, dropping by roughly -8%.

Terra Tech Corp (OTCMKTS:TRTC) pulled in sales of $10.3M in its last reported quarterly financials, representing top line growth of 48.3%. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($1.2M against $27.6M, respectively).


Medical Marijuana Inc (OTCMKTS:MJNA)

Medical Marijuana Inc bills itself as an investment holding company that operates in the medical marijuana and industrial hemp markets.

The company has been one to chronically overpromise and underdeliver, so it warrants caution. Management has been claiming big revenues for many years. Yet the stock has kept trending lower and the company refuses to move off the pink sheets or start producing audited financial data.

Those, taken together, represent some important red flags. MJNA may be best left alone despite its claims of powerhouse progress. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($6.5M against $10.8M, respectively).


This article is part of Networks. Read the Networks Disclaimer.

Continue Reading


A Fresh Look at ISW Holdings (ISWH)



One stock we have covered in the past that seems to be finally clicking on a new level is ISW Holdings Inc (OTCMKTS:ISWH). Hence, we thought it was a good time to take a fresh look at the stock as it ramps higher.

The name was interesting to us late last year when we saw the vestiges of clear turnaround in play in a very speculative penny name. It’s not normal to see a stock like this starting to talk about EBITDA profitability and major sequential quarterly growth data over multiple quarters. What was starting to become clear at that point is becoming even more clear now: this company is an emerging leader in the growing home healthcare space.

ISW Holdings Inc (OTCMKTS:ISWH) characterizes itself as a diversified branding model with a range of sector targets. And we wouldn’t be surprised to see some new dimensions emerge here – for example, ISWH management has talked about developing progress in the data center and alternative energy markets, and has already developed technology with a partner (Bengala) in the supply chain management space.

But the bread and butter right now is clearly centered on its growing role as home healthcare services provider.


Real Growth, Now

According to the most recent release from ISWH, “for the year ended December 31, 2019, ISW Holdings posted revenues of $527,151. Management notes that these results were achieved on accelerating sequential quarterly growth, with nearly half of those revenues appearing in Q4. Sequential growth in Q3 (versus Q2) was 26%. Sequential growth in Q4 (versus Q3) was 29%. The Company projects Sequential growth in Q1 2020 to come in at a new record level significantly outpacing Q4 2019 results.”

The path from here, if we extrapolate, puts a top line of over $2M in play for Q2 2021, and an annual top-line of over $5M for 2021 overall. With that in mind, consider how the company’s leadership summarized the recent trend to close out its most recent release:

“We are all in this together,” commented Alonzo Pierce, President of ISW Holdings. “As far as performance, we hope current and prospective shareholders understand that we are expanding to catch up with an accelerating flood of demand in our home healthcare segment. We are on pace for easily our best year in Company history. We are also on the verge of an announcement that will qualitatively bolster that trajectory, and we will have more details on that very soon.”

That last sentence suggests something big is on the way. That anticipatory sense is also probably helping to stoke the momentum in play right now.

We won’t speculate. But we can say that the stock is almost ridiculously underpriced at its current levels according to a price-to-sales valuation method if one thinks in terms of forward sales by extrapolating its sequential quarterly growth trend.

Since that trend has been holding up successfully for at least 4 quarters at this point, that makes for a reasonable basis for extending the momentum above current levels. With a float under 2.5 million shares, any kind of upside acceleration would have the potential to feed on itself.

The main point here is this: the crowd hasn’t really found ISWH yet. But it has posted strong growth over an extended period on the back of a valid structural theme, improving market positioning, and recent talk of a multi-state expansion.

The float is small, which could serve to ignite a scramble for shares as momentum picks up. Helping to fuel that possibility, the company has hinted at a major announcement to come.


This article is part of Networks. Read the Networks Disclaimer.

Continue Reading

Whats Hot